VICPOTCPharmaceutical PreparationsFiscal year ends December 31
Vicapsys Life Sciences, Inc.
Financials through Q3 FY2024, quarter ended Sep 30, 2024Last filing: 10-Q on Jan 10, 2025
$0.40+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $13.73M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Vicapsys Life Sciences's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wildcat Capital Management, LLC | 6,070,588 | 18.80% | 13G (passive) | Apr 20, 2020 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Leonard Potter | 10% owner | 6,070,588 | 18.75% | Mar 21, 2025 |
| Wildcat Partner Holdings, LP | 10% owner | – | – | Mar 21, 2025 |
| Wildcat Capital Management, LLC | 10% owner | – | – | Mar 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Yurkowski Director | Sep 3, 2010 | Sale | −5,000 | $0.15 | $750 | 760,000 |
| Michael Yurkowski Director | Aug 9, 2010 | Sale | −20,000 | $0.20 | $4.00K | 765,000 |
| Michael Yurkowski Director | Jan 26, 2010 | Award | −5,000 | $0.60 | $3.00K | 785,000 |
| Michael Yurkowski Director | Jan 14, 2010 | Sale | −5,000 | $0.50 | $2.50K | 790,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.